

A VERSATILE AND STEREOSPECIFIC SYNTHESIS OF A DIHYDROXYETHYLENE DIPEPTIDE ISOSTERE OF RENIN INHIBITORS FROM D-RIBOSE


Ming Fai Chan* and Chi-Nung Hsiao§

Process Research, Chemical and Agricultural Products Division,
Abbott Laboratories, North Chicago, IL 60064, U.S.A.

Summary: (2*S*,3*R*,4*S*)-2-amino-1-cyclohexyl-6-methylheptane-3,4-diol, a dihydroxyethylene dipeptide isostere for renin inhibitors, was synthesized from D-ribose stereospecifically. This method can be readily adapted to other dihydroxyethylene isosteres.

Renin inhibitors have attracted a great deal of interest in medicinal chemistry due to their potential use as antihypertensive agents.¹ The dihydroxyethylene dipeptide isostere **1** found in a number of renin inhibitors was designed as a transition state mimic of the scissile Leu-Val bond in angiotensinogen.² Although several syntheses of this important molecule have been published,³ they all involve asymmetric induction from an existing chiral center(s) which in some cases resulted in the formation of a mixture of diastereoisomers and hence complicated separations. Herein we report a stereospecific synthesis of the title compound from D-ribose **2** in which the three stereo centers of the sugar are incorporated into those of **1** by stereochemically well-defined reactions.

Our strategy takes advantage of the fact that the 2- and 3-OH groups in D-ribose **2** have the same absolute stereochemistry as the dihydroxyethylene moiety in **1**. The synthesis thus involves the replacement of the 4-OH group by an amine with inversion of configuration and the formation of two carbon-carbon bonds at C-1 and C-5 of **2** (Scheme 1). The 4-OH group where the inversion of configuration is to take place can be distinguished from the other hydroxyl groups by the preferential formation of the hemiacetal furanose form of D-ribose **2a**. Once in the cyclized form, the 2- and 3-OH groups can be easily protected as the acetonide **4a**. Furthermore the 5-OH group, being less hindered, can then be readily differentiated from the hemiacetal OH group.




Scheme 1

*Present address: ImmunoPharmaceutics, Inc., 11011 Via Frontera, San Diego, CA 92127

§Pharmaceutical Products Division


The 2- and 3-OH groups of D-ribose **2** were protected as the furanose acetonide **3** according to a literature method ^{4b}. The crude acetonide **3** was converted into the 5-tosylate **4**^{5a,b} selectively, m.p. 92–94 °C, $[\alpha]^{25}_D +1.5^\circ$ ($c=1.00$, MeOH) in 69% overall yield from **2**. On treatment with 2.2 equivalents of the ylide derived from isopropyltriphenylphosphonium iodide⁶ at 0 °C, the epoxyalkene **5**,^{5a,b} $[\alpha]^{25}_D +28.1^\circ$ ($c=1.00$, MeOH) was obtained directly from **4** (62% yield). To the best of our knowledge, the simultaneous formation of an epoxide and an olefin directly from a ribose derivative is not well precedented in the literature.⁷ The epoxide **5** was then opened with cyclohexyl magnesium chloride using CuI as a catalyst⁸ (THF, -20 °C, 72%) to give the alcohol **6**,^{5a,b} m.p. 84–6 °C, $[\alpha]^{25}_D +48.6^\circ$ ($c=1.18$, MeOH) which was hydrogenated to give the saturated alcohol **7**,^{5a,b} m.p. 50–2 °C, $[\alpha]^{24}_D -3.4^\circ$ ($c=1.12$, MeOH) quantitatively. Conversion of the hydroxyl group in **7** into the azide **8** turned out to be exceptionally difficult, presumably due to its sterically hindered environment. Under most conditions, the elimination product **9** predominated. The best result was obtained under Mitsunobu conditions with diphenylphosphoryl azide⁹ (Ph₃P, DEAD, THF), which gave ca. 40% yield of a 1:1 mixture of the azide **8** and the olefin **9**. This mixture was hydrogenated in the presence of di-*tert*-butyl dicarbonate (10% Pd/C, EtOAc) to afford the fully protected isostere **1a**^{5a,b} and the acetonide **10**^{5a} in 35 and 40% yield respectively (Scheme 2).



Scheme 2

Reagents and conditions: a) Ref. 4b; b) TsCl, pyridine, CH₂Cl₂, 25 °C, 24 h, 69% from **2a**; c) 2.2 equi (CH₃)₂CHPPH₃⁺ I⁻, 2.2 equi BuLi, THF, 0–25 °C, 3 h, 62%; d) *o*-C₆H₁₁MgCl, cat. CuI, THF, -40 °C, 2 h, 72%; e) H₂, Pd/C, MeOH, 25 °C, 3 h, 100%; f) (PhO)₂P(O)N₃, Ph₃P, DEAD, THF, 24 h, 40%, ca. 1:1 mixture; g) H₂, Pd/C, 1.5 equi (*t*-BuOCO)₂O, EtOAc, 14 h

In order to improve the yield of the synthesis, we elect to invert the C-4 chiral center (ribose numbering) by means of a proximal nitrogen nucleophile before the cyclohexyl group is introduced. Accordingly, the epoxide **5** was hydrogenated to give **11**,^{5a,b} b p 120-5 °C (bath)/1.5 torr, $[\alpha]_D^{24} +7.4^\circ$ ($c=1.04$, MeOH) and opened with azide ion¹⁰ (NaN_3 , NH_4Cl , $\text{EtOCH}_2\text{CH}_2\text{OH}/\text{H}_2\text{O}$, reflux 1 h, 85%) at the less hindered position to afford the azidoalcohol **12**^{5a,b}, $[\alpha]_D^{24} -27.8^\circ$ ($c=1.04$, MeOH) exclusively. The azide **12** was reduced (H_2 , 10% Pd/C) to the corresponding amine and was protected *in situ* as the *t*-butoxycarbonyl (Boc) derivative **13**,^{5a,b} $[\alpha]_D^{24} +2.9^\circ$ ($c=1.00$, MeOH) in 92% overall yield. After conversion of the alcohol **13** into the mesylate **14**,^{5a,b} m p 109.5-111 °C, $[\alpha]_D^{24} +48.6^\circ$ ($c=1.00$, MeOH), cyclization took place smoothly in DMF in the presence of sodium hydride to form the *N*-Boc aziridine **15**^{5a}, $[\alpha]_D^{24} -17.0^\circ$ ($c=1.03$, MeOH) in 83% yield. Thus, the stereochemistry at C-4 was inverted in this $\text{S}_{\text{N}}2$ reaction. It is interesting to note that **14** failed to cyclize under identical conditions in THF even at boiling temperature. Alternatively and more efficiently, the azidoalcohol **12** was reacted with Ph_3P in refluxing toluene to give the *N*-unsubstituted aziridine directly¹¹ which on acylation with di-*tert*-butyl dicarbonate gave **15** in 75% overall yield from **12**. The spectroscopic properties and optical rotation of the product **15**^{13b} obtained in this case is identical to that obtained through the mesylate, thus indicating that an inversion of configuration has occurred at C-2. The cyclohexyl group was introduced via a cuprate opening¹² of the *N*-Boc aziridine **15** (lithium dicyclohexyl cuprate, THF, -40 °C) to give the fully protected dihydroxyethylene isostere **1a**, $[\alpha]_D^{24} -38.4^\circ$ ($c=1.14$, MeOH)^{13a} in 80% yield. The title compound **1** was obtained by hydrolysis of **1a** as a viscous oil which without purification was converted to the *N*-Boc amino diol **1b**. Compound **1b** is identical (NMR, IR, TLC, $[\alpha]_D^{24}$) to an authentic sample^{3a} (Scheme 3).



Scheme 3

Reagents and conditions a) H_2 , 10% Pd/C, EtOAc, 25 °C, 2 h, 91%; b) NaN_3 , NH_4Cl , $\text{MeOCH}_2\text{CH}_2\text{OH}/\text{H}_2\text{O}$, reflux, 1 h, 85%; c) H_2 , 10% Pd/C, EtOAc, $(t\text{-BuOCO})_2\text{O}$, 25 °C, 2 h, 92%; d) MsCl , Et_3N , CH_2Cl_2 , 0 °C; e) NaH , DMF, 25 °C, 2 h, 82% for two steps; f) Ph_3P , toluene, reflux, 6 h; then $(t\text{-BuOCO})_2\text{O}$, 85% overall from **12**; g) $(c\text{-C}_6\text{H}_{11})_2\text{CuMgX}$, THF, -40 °C, 2 h, 80%; h) TFA/ H_2O , 25 °C, 16 h, 55 °C, 1 h; i) $(t\text{-BuOCO})_2\text{O}$, $\text{CH}_2\text{Cl}_2/\text{H}_2\text{O}$, 2 h.

Thus, we have developed a versatile synthesis of the protected amino diol **1b** from D-nbose in 22% overall. It is noteworthy that the key reactions used in this synthesis are regio- and stereospecific and hence no diastereoisomers were formed. This synthesis can be readily adapted to a wide variety of dihydroxyethylene isosteres simply by changing the Wittig reagent and the organocuprate used.

References and Notes.

- For a review, see Greenlee, W. J. *Pharm. Res.* **1987**, *4*, 364; *Med. Res. Rev.* **1990**, *10*, 173.
- Luly, J. R.; BaMaung, N.; Soderquist, J.; Fung, A. K. L.; Stein, H.; Kleinert, H. D.; Marcotte, P. A.; Egan, D. A.; Bopp, B.; Merits, I.; Bolis, G.; Greer, J.; Perun, T. J.; Plattner, J. J. *J. Med. Chem.* **1988**, *31*, 2264.
- a) Luly, J. R.; Hsiao, C.-N.; BaMaung, N.; Plattner, J. J. *J. Org. Chem.* **1988**, *53*, 6109;
b) Wood, J. L.; Jones, D. R.; Hirschmann, R.; Smith, A. B., III. *Tetrahedron Lett.* **1990**, *31*, 6329;
c) Kobayashi, Y.; Nakatani, K.; Ito, Y.; Terashima, S. *Chem. Lett.* **1990**, 1709.
- a) Levene, P. A.; Stiller, E. T. *J. Biol. Chem.* **1933**, *102*, 187;
b) Kaskar, B.; Heise, G. L.; Michalak, R. S.; Vishnuvajjala, B. R. *Synthesis* **1990**, 1031.
- a) The ^1H NMR, IR and mass spectra were consistent with the assigned structure;
b) A satisfactory elemental analysis was obtained for an appropriately purified sample.
- Wittig, G.; Wittenberg, D. *Liebigs Ann. Chem.* **1957**, *606*, 1.
- A related example was brought to our attention by a referee: Smith, A. B., III; Rano, T. A.; Chida, N.; Sulikowski, G. A. *J. Org. Chem.* **1990**, *55*, 1136.
- Huyuh, C.; Derguini-Boumechal, F.; Linstrumelle, G. *Tetrahedron Lett.* **1979**, 1503.
- Lal, B.; Pramanik, B. N.; Manhas, M. S.; Bose, A. K. *Tetrahedron Lett.* **1977**, 1777.
- Behrens, C. H.; Soo, Y. K.; Sharpless, K. B.; Walker, F. J. *J. Org. Chem.* **1985**, *50*, 5687.
- Ittah, Y.; Sasson, Y.; Shahak, I.; Tsaroom, S.; Blum, J. *J. Org. Chem.* **1978**, *43*, 4271.
- a) Eis, M. J.; Ganem, B. *Tetrahedron Lett.* **1985**, *26*, 1153;
b) Dureault, A.; Greck, C.; Depezay, J.-C. *ibid.* **1986**, *27*, 4157;
c) Dureault, A.; Tranchepain, I.; Greck, C.; Depezay, J.-C. *ibid.* **1987**, *28*, 3341;
d) Dureault, A.; Tranchepain, I.; Depezay, J.-C. *J. Org. Chem.* **1989**, *54*, 5324.
- Spectral data:
a) Compound **1a**: ^1H NMR (300 MHz, CDCl_3): δ 0.75-2.0 (H, m), 0.93 (6H, app t, $J = 6$ Hz), 1.35 (3H, s), 1.45 (9H, s), 1.49 (3H, s), 3.7-3.8 (1H, m), 3.99 (1H, br d, $J = 6$ Hz), 4.23 (1H, ddd, $J = 4, 7.5, 10.5$ Hz), 4.67 (1H, br d, $J = 9$ Hz), CIMS m/z 384 ($M+1$, 100%), 328 (16), 310 (14), 284 (17), HRMS calcd for $\text{C}_{22}\text{H}_{42}\text{NO}_4+\text{H}$: 384.3114, found: 384.3106;
b) Compound **15**: ^1H NMR (300 MHz, CDCl_3): δ 0.94 (3H, d, $J = 6.6$ Hz), 0.98 (3H, d, $J = 6.6$ Hz), 1.3-1.4 (1H, m), 1.36 (3H, s), 1.46 (9H, s), 1.55 (3H, s), 1.65-1.85 (2H, m), 1.99 (1H, d, $J = 3.8$ Hz, $\alpha\text{S N-CH}_2$), 2.30 (1H, d, $J = 6.3$ Hz; trans N-CH_2), 2.51 (1H, ddd, $J = 3.8, 6.3$ and 8.5 Hz, N-CH_2), 3.55 (1H, dd, $J = 5.7, 8.5$ Hz, $\text{CH}_2\text{-CH-O}$) and 4.23 (1H, ddd, $J = 4, 5.7, 9.6$ Hz; CH-CH-O), CIMS. m/z 300 ($M+1$, 100%), 200 (55%); HRMS calcd for $\text{C}_{16}\text{H}_{29}\text{NO}_4+\text{H}$ 300.2175, found: 300.2180.